Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Soratinex (also known as Dr. Michaels) is a topical, steroid-free treatment system developed for the management of chronic plaque psoriasis. The system consists of three distinct products used in sequence: a cleansing gel, an ointment, and a skin conditioner. The formulation is based on a proprietary blend of natural ingredients, including essential oils, herbal extracts, and minerals. It is designed to provide a long-term management solution for psoriasis by removing psoriatic scales, reducing inflammation, and hydrating the skin to prevent recurrences. Clinical studies have demonstrated that Soratinex can be more effective than high-potency corticosteroids like methylprednisolone aceponate for long-term disease control, with a significantly lower risk of side effects. In many European jurisdictions, it is registered and marketed as a Class I medical device.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Soratinex.